Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
Figure 4
Profile of expression of galectins through PCa evolution. Radical prostatectomies were classified according to TNM scale. Specimens () covered all stages of prostate cancer evolution, including T1 (tumor detected in less or 5% of the tissue), T2 (tumor confined to the prostate), T3 (tumor that extends beyond the prostatic capsule), and T4 (tumor that invades structures other than seminal vesicles), in addition to BHP. Immunohistochemistry was conducted on paraffin-embedded tissue samples as previously described [23]. The figure shows proportional expression of each Gal at different stages of PCa.
